Bendamustine + Rituximab

DRUG3 trials

Sponsors

Gruppo Italiano Malattie EMatologiche dell'Adulto, Peking Union Medical College Hospital, The First Affiliated Hospital with Nanjing Medical University

Conditions

Chronic Lymphocytic LeukemiaMarginal Zone Lymphoma(MZL)Waldenström's Macroglobulinemia (WM)

Phase 2

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

RecruitingNCT07208981

The First Affiliated Hospital with Nanjing Medical UniversityMarginal Zone Lymphoma(MZL)

Start: 2025-08-14End: 2031-06-01Target: 169Updated: 2025-10-06

Unknown Phase

Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia

CompletedNCT02491398

Gruppo Italiano Malattie EMatologiche dell'AdultoChronic Lymphocytic Leukemia

Start: 2016-02-29End: 2017-01-31Updated: 2020-10-06

Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia

Not yet recruitingNCT06942507

Peking Union Medical College HospitalWaldenström's Macroglobulinemia (WM)

Start: 2025-05-01End: 2029-04-30Target: 104Updated: 2025-04-30